title: [Successful long-term control of recurrent primary central nervous system anaplastic large cell lymphoma after autologous hematopoietic stem cell transplantation with concurrent whole brain and spinal cord radiotherapy].
abstract: A 24-year-old woman was hospitalized with seizures in 2002. Magnetic resonance imaging demonstrated an intraspinal mass and inhomogeneous gadolinium enhancement along the cerebrospinal meninges. Cerebrospinal fluid (CSF) cytology showed large atypical cells expressing CD2, cytoplasmic CD3, CD7, CD13 and CD30. The patient was finally diagnosed with primary central nervous system anaplastic large cell lymphoma (ALCL). She completed 5 courses of methotrexate (MTX)/ procarbazine (PCZ)/ vincristine (VCR) (MPV) chemotherapy, followed by 2 courses of high dose cytarabine (AraC) and achieved a complete remission. In 2003, she suffered from headache. CSF analysis showed atypical lymphoid cells expressing CD 30. First CNS relapse was diagnosed. She then underwent autologous peripheral blood stem cell transplantation (auto-PBSCT) after administration of thiotepa, buslfan, and cyclophosphamide. However, second CNS relapse occurred in 2004. She received 5 courses of MPV chemotherapy followed by 36 Gy of craniospinal irradiation. Although there was no recurrence of the CNS disease, a third relapse was detected in the right breast in 2009. Pathological and immunohistochemistry analysis revealed ALK-1 positive ALCL. She was treated with 6 courses of cyclophosphamide/adriamycin/vincristine/predonine (CHOP) chemotherapy and 30.6 Gy of local radiation therapy. She has remained in remission for 6 years, to date, since the last therapy and has an excellent quality of life.
authors.affiliation: Department of Hematology, Nagano Red Cross Hospital.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Hiroshima
authors.forename: Hiroko
authors.initials: H
authors.lastname: Kaiume
authors.forename: Takehiko
authors.initials: T
authors.lastname: Kirihara
authors.forename: Wataru
authors.initials: W
authors.lastname: Takeda
authors.forename: Taro
authors.initials: T
authors.lastname: Kurihara
authors.forename: Keijiro
authors.initials: K
authors.lastname: Sato
authors.forename: Ikuo
authors.initials: I
authors.lastname: Shimizu
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Ueki
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sumi
authors.forename: Mayumi
authors.initials: M
authors.lastname: Ueno
authors.forename: Naoaki
authors.initials: N
authors.lastname: Ichikawa
authors.forename: Naoko
authors.initials: N
authors.lastname: Asano
authors.forename: Masahide
authors.initials: M
authors.lastname: Watanabe
authors.forename: Hikaru
authors.initials: H
authors.lastname: Kobayashi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult